358 related articles for article (PubMed ID: 37395226)
1. Avatrombopag increased platelet count in a patient with chronic immune thrombocytopenia refractory to multiple lines of treatment.
Lebowa W; Zdziarska J; Sacha T
Blood Coagul Fibrinolysis; 2023 Jul; 34(5):327-332. PubMed ID: 37395226
[TBL] [Abstract][Full Text] [Related]
2. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
3. Avatrombopag: A Review in Thrombocytopenia.
Markham A
Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
[TBL] [Abstract][Full Text] [Related]
4. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
Maitland HS
Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
[TBL] [Abstract][Full Text] [Related]
5. Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia.
Jain S; Gernsheimer T; Kolodny S; Bernheisel C; Vredenburg M; Panch SR
Platelets; 2023 Dec; 34(1):2195016. PubMed ID: 37013676
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.
Wojciechowski P; Wilson K; Nazir J; Pustułka I; Tytuła A; Smela B; Pochopien M; Vredenburg M; McCrae KR; Jurczak W
Adv Ther; 2021 Jun; 38(6):3113-3128. PubMed ID: 33934279
[TBL] [Abstract][Full Text] [Related]
7. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.
Al-Samkari H; Nagalla S
Platelets; 2022 Feb; 33(2):257-264. PubMed ID: 33586606
[TBL] [Abstract][Full Text] [Related]
10. Severe romiplostim-induced rebound thrombocytopenia after splenectomy for refractory ITP.
Choe MJ; Packer CD
Ann Pharmacother; 2015 Jan; 49(1):140-4. PubMed ID: 25325908
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
[TBL] [Abstract][Full Text] [Related]
12. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Gao Y; Gong M; Zhang C; Kong X; Ma Y
Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
[TBL] [Abstract][Full Text] [Related]
13. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
[TBL] [Abstract][Full Text] [Related]
14. Avatrombopag for the treatment of immune thrombocytopenia.
Długosz-Danecka M; Zdziarska J; Jurczak W
Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real-world study in China.
Cheng X; Wang Z; Dong S; Ma J; Meng J; Wang X; Wu R
Br J Haematol; 2023 Aug; 202(3):636-644. PubMed ID: 37188335
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
Yang R; Lin L; Yao H; Ji O; Shen Q
Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
[TBL] [Abstract][Full Text] [Related]
17. Avatrombopag for adults with early versus chronic immune thrombocytopenia.
Virk ZM; Leaf RK; Kuter DJ; Goodarzi K; Connell NT; Connors JM; Al-Samkari H
Am J Hematol; 2024 Feb; 99(2):155-162. PubMed ID: 38063420
[TBL] [Abstract][Full Text] [Related]
18. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
[TBL] [Abstract][Full Text] [Related]
19. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
20. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
